Big Data Probably Knows More About You Than Your Friends Do

Big Data Probably Knows More About You Than Your Friends Do

A representation of the digital lifestyle prevalent today that enables the collection of a wealth of data.

(© zapp2photo/Fotolia)


Keep Reading Keep Reading
Jennifer Miller
Jennifer E. Miller, PhD, is an Assistant Professor in NYU School of Medicine and President of the nonprofit Bioethics International. She is also the Creator of the Good Pharma Scorecard, an index that ranks new drugs and pharmaceutical companies on their ethics performance. She is also a member of The World Economic Forum and serves on NYU’s Pharmacy and Therapeutics Committee and stem cell research oversight board. Prior to joining NYU’s faculty, Dr. Miller was based at Duke University and Harvard University and served on the CDC Task Force for Pediatric Emergency Mass Critical Care, the AMA Advanced Disaster Life Support Education Consortium, as a consultant to the UN Economic and Social Council, and on the PCORI-NIH Collaboratory. A prolific writer, Dr. Miller has authored over 40 publications, including for Nature Medicine, Health Affairs, and The Scientist. She was a Fox News pundit from 2009 to 2012 and remains a commentator on CBS news, Wall Street Journal, Washington Post, Bloomberg News, Forbes, Dr. Oz and NPR.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.